Amneal Pharmaceuticals Inc. has bought a small portfolio of drugs from fellow U.S. biotech Saol Therapeutics Inc., adding the skeletal muscle relaxant baclofen to its portfolio and boosting its pipeline with a potential therapy to treat spasticity in a deal worth $83.5 million plus royalties.